EP Patent

EP3045043A1 — Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Assigned to Relmada Therapeutics Inc · Expires 2016-07-20 · 10y expired

What this patent protects

The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.

USPTO Abstract

The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3045043A1
Jurisdiction
EP
Classification
Expires
2016-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Relmada Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.